Evidence map›Paper›PMID 22327343›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2012

Evaluation of a digital microfluidic real-time PCR platform to detect DNA of Candida albicans in blood.

W A Schell, J L Benton, P B Smith, M Poore, J L Rouse, D J Boles, M D Johnson, B D Alexander, V K Pamula, A E Eckhardt and 4 more

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Nucleic Acid Amplification Tests forPathogens (Basel, Switzerland) · 2026
    Pooled it
  2. Pooled it
  3. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Guideline
  4. Review
  5. Article
  6. Article
  7. Review
  8. Performance of a Real-Time PCR Assay for the Detection of FiveJournal of fungi (Basel, Switzerland) · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Molecular Diagnosis of Yeast Infections.Current fungal infection reports · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Direct Detection ofSensors (Basel, Switzerland) · 2018
    Article
  20. Digital Microfluidics for Nucleic Acid Amplification.Sensors (Basel, Switzerland) · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

W A SchellDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
J L Benton
P B Smith
M Poore
J L Rouse
D J Boles
M D Johnson
B D Alexander
V K Pamula
A E Eckhardt
M G Pollack
D K Benjamin
J R Perfect
T G Mitchell
Advanced Liquid Logic · USDuke Medical Center · USDuke University · USDuke University Hospital · US

Funding

Microfluidic PCR Platform to Detect Microbial DNAU01AI066590 · NIAID · DUKE UNIVERSITY · PI MITCHELL, THOMAS G. · 2005 to 2009
$3.0M
Mid-Career Investigator Award: Preventing and Diagnosing Fungal DiseaseK24AI072522 · NIAID · DUKE UNIVERSITY · PI ALEXANDER, BARBARA D · 2007 to 2011
$583k
NIAID NIH HHS K24 AI 072522NIAID NIH HHS K24 AI072522NIAID NIH HHS U01 AI 066590NIAID NIH HHS U01 AI066590
6 · The paper itself

Abstract

Species of Candida frequently cause life-threatening infections in neonates, transplant and intensive care unit (ICU) patients, and others with compromised host defenses. The successful management of systemic candidiasis depends upon early, rapid diagnosis. Blood cultures are the standard diagnostic method, but identification requires days and less than half of the patients are positive. These limitations may be eliminated by using real-time polymerase chain reaction (PCR) to detect Candida DNA in the blood specimens of patients at risk. Here, we optimized a PCR protocol to detect 5-10 yeasts in low volumes of simulated and clinical specimens. We also used a mouse model of systemic candidiasis and determined that candidemia is optimally detectable during the first few days after infection. However, PCR tests are often costly, labor-intensive, and inconvenient for routine use. To address these obstacles, we evaluated the innovative microfluidic real-time PCR platform (Advanced Liquid Logic, Inc.), which has the potential for full automation and rapid turnaround. Eleven and nine of 16 specimens from individual patients with culture-proven candidemia tested positive for C. albicans DNA by conventional and microfluidic real-time PCR, respectively, for a combined sensitivity of 94%. The microfluidic platform offers a significant technical advance in the detection of microbial DNA in clinical specimens.

Indexed as

AnimalsCandida albicansCandidemiaClinical Laboratory TechniquesDisease Models, AnimalHumansMiceMicrofluidicsReal-Time Polymerase Chain ReactionSensitivity and Specificity

Identifiers

PMID22327343
PMCPMC3939829
OpenAlexW1996152388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.